Clonidine
Tablet (XR Kapvay): 0.1 mg
Suspension (XR Onyda XR): 0.1 mg/mL
Patch (Catapres-TTS): -1, -2, -3 (0.1, 0.2, 0.3 mg/day weekly)
Epidural (Duraclon): 100 & 500 mcg/mL
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Hypertension — Catapres tablet & Catapres-TTS patch | Adults | Monotherapy or with other antihypertensives | FDA Approved |
| Attention-deficit/hyperactivity disorder (ADHD) — Kapvay ER tablet (twice daily) and Onyda XR oral suspension (once nightly) | Children and adolescents 6–17 years | Monotherapy or adjunctive to a CNS stimulant | FDA Approved |
| Severe pain in cancer patients — Duraclon (epidural) | Adults inadequately relieved by epidural or systemic opioids alone | Adjunctive epidural infusion with opiates | FDA Approved |
| Opioid withdrawal symptom control | Adults and adolescents | Monotherapy or with other supportive medications | Off-Label |
| Tourette syndrome / chronic tic disorders | Children, adolescents, and adults | Monotherapy | Off-Label |
| Menopausal vasomotor symptoms (hot flashes) | Adults (incl. tamoxifen-related hot flashes) | Non-hormonal alternative | Off-Label |
Clonidine was first approved in the United States in 1974 for hypertension and remains widely used despite no longer being a first-line antihypertensive in the 2017 ACC/AHA guideline. Its principal modern roles include: a non-stimulant option for paediatric ADHD (Kapvay tablet approved 2010, Onyda XR oral suspension approved 2024); sympatholytic symptom control during opioid and alcohol withdrawal; an adjunct for refractory cancer pain when given epidurally (Duraclon); and a non-hormonal option for vasomotor symptoms of menopause. Clonidine retains a useful role in resistant hypertension, perioperative sympathetic management, and ambulatory hypertensive urgency.
Opioid withdrawal — long-standing standard adjunct supported by Cochrane review evidence in inpatient and outpatient detoxification. Evidence quality: moderate.
Alcohol withdrawal — adjunctive sympatholytic — useful for autonomic hyperactivity but not a substitute for benzodiazepines for seizure prevention. Evidence quality: low–moderate.
Tourette syndrome / chronic tic disorders — supported by the AAN 2019 practice guideline as a treatment option for tics. Evidence quality: moderate.
Menopausal hot flashes — small effect size; the North American Menopause Society lists clonidine as a non-hormonal option but not first-line versus SSRIs/SNRIs or gabapentin. Evidence quality: low–moderate.
Adult ADHD adjunctive therapy, PTSD-related hyperarousal and nightmares, anxiety in autism spectrum disorder, perioperative anxiolysis or anaesthesia adjunct, and smoking cessation — commonly prescribed; evidence largely from small trials and case series. Evidence quality: low.
Dosing
Clonidine formulations are not interchangeable on a milligram-for-milligram basis. The extended-release tablet (Kapvay) and oral suspension (Onyda XR) for ADHD differ in pharmacokinetics from the immediate-release tablet (Catapres). The transdermal patch achieves steady state only after approximately 3 days. Doses are presented in milligrams except for epidural Duraclon, where micrograms are standard.
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Hypertension — adults (Catapres IR tablet) | 0.1 mg PO BID (morning & bedtime) | 0.2–0.6 mg/day in divided doses | 2.4 mg/day (rarely used) | Increase by 0.1 mg/day at weekly intervals; place the larger split at bedtime to reduce daytime sedation Elderly patients may benefit from a lower starting dose |
| Hypertension — adults (Catapres-TTS transdermal) | TTS-1 (0.1 mg/day) once weekly | TTS-1 to TTS-3 (0.1–0.3 mg/day) weekly | 0.6 mg/day (two TTS-3 patches) | Steady state at ~3 days; an oral-to-patch overlap of 2–3 days is commonly used in clinical practice when transitioning Apply to hairless skin on upper outer arm or chest; rotate site weekly |
| ADHD — children and adolescents 6–17 yr (Kapvay XR tablet) | 0.1 mg PO at bedtime | 0.1–0.4 mg/day divided BID | 0.4 mg/day | Increase by 0.1 mg/day at weekly intervals; bedtime dose must equal or exceed the morning dose Doses >0.4 mg/day not evaluated; tablets must be swallowed whole |
| ADHD — children and adolescents ≥6 yr (Onyda XR oral suspension) | 0.1 mg (1 mL) once nightly at bedtime | 0.1–0.4 mg once nightly | 0.4 mg once nightly | Increase by 0.1 mg/day at weekly intervals; supplied as 0.1 mg/mL orange-flavoured suspension Once-daily nighttime dosing differentiates Onyda XR from Kapvay BID |
| Severe cancer pain (Duraclon epidural, adults) | 30 mcg/h continuous epidural infusion | Titrated to analgesic response | Individualized; experience >40 mcg/h is limited | Used in combination with epidural opioids; close BP and HR monitoring required for the first few days Pediatric epidural use described per kg basis (0.5 mcg/kg/h) per the Duraclon label |
| Opioid withdrawal (off-label, adults) | 0.1 mg PO every 4–6 h as needed | 0.1–0.3 mg every 6–8 h scheduled | ~1.2 mg/day | Hold for SBP <90 mmHg or HR <60 bpm; taper over 5–7 days as withdrawal resolves Combine with symptomatic agents (loperamide, ondansetron, NSAIDs) |
| Tourette syndrome / chronic tic disorder (off-label, paediatric) | Typically 0.05 mg PO at bedtime | 0.1–0.4 mg/day divided BID–TID | ~0.4 mg/day | Slow titration over 4–6 weeks; clinical response often gradual Reassess at 8–12 weeks; AAN 2019 supports use without specifying a fixed regimen |
| Menopausal hot flashes (off-label, adults) | 0.05–0.1 mg PO BID, or TTS-1 weekly | 0.1–0.2 mg/day | ~0.4 mg/day | Effect modest (~1 flash/day reduction vs placebo) Consider alternatives (SSRI/SNRI, gabapentin) before clonidine |
| Switching between formulations | Do not substitute mg-for-mg; titrate the new formulation per its own schedule | Each PI specifies that mg-for-mg substitution is not recommended Use a 2–3 day overlap clinically when transitioning oral to patch | ||
Dose Adjustments in Special Populations
| Population | Recommendation | Rationale |
|---|---|---|
| Renal impairment (significant) | Lower starting dose; titrate cautiously per response | 40–60% renal excretion of unchanged drug; t½ rises to ~41 h in severe impairment |
| Hemodialysis | Standard dose; no supplemental dose post-dialysis | Clonidine is poorly dialyzed |
| Hepatic impairment | Consider lower starting dose; monitor closely | Approximately half of clearance is hepatic |
| Elderly | Start at the lowest dose; titrate slowly | Greater orthostatic hypotension and fall risk; reduced renal clearance common |
| Pediatric ADHD — below 6 years | Not established | Safety and efficacy not studied for Kapvay or Onyda XR in this age group |
| Perioperative | Continue Catapres up to 4 h before surgery; resume promptly | Per Catapres PI; abrupt cessation around surgery risks rebound hypertension |
Discontinuation
Clonidine should never be stopped abruptly. The Kapvay and Onyda XR labels specify tapering by no more than 0.1 mg every 3–7 days. The Catapres tablet label recommends gradual reduction over 2–4 days. Risk of rebound is highest at higher doses, with concomitant beta-blocker therapy, and after prolonged use. Hypertensive encephalopathy, cerebrovascular accident, and death have been reported after abrupt clonidine withdrawal — particularly when the patient has continued a beta-blocker.
Across both adult hypertension (Catapres) and paediatric ADHD (Kapvay), the larger portion of the daily dose is placed at bedtime to minimize daytime sedation while maintaining overnight sympathetic suppression and morning blood-pressure control. The Kapvay PI codifies this with a fixed bedtime-loaded split (e.g., 0.3 mg/day = 0.1 mg AM + 0.2 mg HS). Onyda XR achieves the same logic by giving the entire daily dose once at bedtime.
Pharmacology
Mechanism of Action
Clonidine is a centrally acting agonist at α2-adrenergic receptors and additionally activates imidazoline I1 receptors in the rostral ventrolateral medulla — a profile distinct from the more α2A-selective guanfacine. Stimulation of presynaptic and brainstem α2 receptors reduces sympathetic outflow from the central nervous system, producing decreases in peripheral vascular resistance, renal vascular resistance, heart rate, and blood pressure; renal blood flow and glomerular filtration rate are essentially unchanged, and postural reflexes are preserved. The same brainstem-mediated reduction in noradrenergic firing accounts for clonidine’s ability to suppress autonomic features of opioid and alcohol withdrawal. The mechanism by which clonidine improves ADHD symptoms is not established. Epidurally, clonidine produces analgesia by activating α2 receptors in the dorsal horn of the spinal cord — an opioid-independent pathway that synergizes with neuraxial opioids. Clonidine is not a known significant inducer or inhibitor of human cytochrome P450 enzymes, which limits the scope of its pharmacokinetic interactions.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Oral bioavailability 70–80%; Tmax 1–3 h (IR tablet); BP fall begins within 30–60 min and peaks at 2–4 h. Transdermal: bioavailability ~60%; steady state at ~3 days. Pharmacokinetics are dose-proportional from 100–600 mcg | IR tablet useful for ambulatory hypertensive urgency; patch unsuited to acute control because of slow onset |
| Distribution | Vd ~2.1 L/kg; protein binding 20–40%; high lipid solubility; crosses the blood-brain and placental barriers; secreted into breast milk | Wide CNS distribution explains both centrally mediated efficacy and sedation; observe nursing infants for sedation |
| Metabolism | ~50% of the absorbed dose metabolized hepatically to inactive metabolites. Published pharmacokinetic literature attributes a predominant role to CYP2D6 in the non-renal clearance of clonidine; however, no clinically significant CYP-mediated drug-drug interactions are listed in the FDA-approved labels for clonidine products | Caution is reasonable when co-prescribing potent CYP2D6 inhibitors, but routine dose adjustment is not specified by the prescribing information |
| Elimination | 40–60% as unchanged drug in urine within 24 h; t½ 12–16 h with normal renal function; up to 41 h in severe renal impairment; therapeutic plasma levels persist ~8 h after patch removal then decline over several days | Dose reduction required in CKD; patch effect washes out gradually after removal |
Side Effects
Clonidine’s adverse-effect profile is dominated by sedation, dry mouth, and cardiovascular effects (hypotension, bradycardia). Sedation and dry mouth are typically more frequent than with guanfacine because of clonidine’s broader α2-receptor activity. Most adverse effects are dose-dependent. Frequencies below come from the Kapvay FDA prescribing information (paediatric ADHD fixed-dose monotherapy Study 1, n=76 at each active dose; flexible-dose adjunctive Study 2) and the Catapres adult hypertension prescribing information. In the Kapvay tables, “somnolence” encompasses both somnolence and sedation, and “fatigue” includes lethargy.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Somnolence/sedation — Kapvay paediatric monotherapy | 38% (0.2 mg) · 31% (0.4 mg) | Versus 4% placebo; usually peaks early and improves with continued therapy |
| Headache — Kapvay paediatric monotherapy | 20% (0.2 mg) · 13% (0.4 mg) | Versus 16% placebo; rates close to placebo at higher doses |
| Fatigue (incl. lethargy) — Kapvay paediatric monotherapy | 16% (0.2 mg) · 13% (0.4 mg) | Versus 1% placebo; distinct from sedation and may persist longer |
| Upper abdominal pain — Kapvay paediatric monotherapy | 15% (0.2 mg) · 10% (0.4 mg) | Versus 12% placebo; consider taking with light food if tolerated |
| Somnolence — Kapvay adjunctive to stimulant | 19% | Versus 7% with placebo plus stimulant |
| Fatigue — Kapvay adjunctive to stimulant | 14% | Versus 4% with placebo plus stimulant |
| Dry mouth — Catapres adult HTN | ~40% | Most frequent dose-related adverse effect; far more frequent with adult IR tablet than with paediatric XR |
| Drowsiness — Catapres adult HTN | ~33% | Bedtime-loaded dosing reduces functional impact |
| Dizziness — Catapres adult HTN | ~16% | Often orthostatic; counsel on positional changes |
| Constipation — Catapres adult HTN | ~10% | Dose-related; manage with hydration, fibre, osmotic laxative if needed |
| Sedation — Catapres adult HTN | ~10% | Distinct adverse-event term in the Catapres PI alongside drowsiness |
| Localized skin reaction — Catapres-TTS transdermal | Common with long-term use | Erythema, vesiculation, contact dermatitis at application site; rotate sites weekly. Patch sensitisation may also produce reactions on switching to oral clonidine |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Irritability — Kapvay paediatric monotherapy | 9% (0.2 mg) · 5% (0.4 mg) | Versus 4% placebo; distinguish from underlying ADHD/mood symptoms |
| Insomnia — Kapvay paediatric monotherapy | 5–6% | Versus 1% placebo; paradoxical despite sedation |
| Nightmare — Kapvay paediatric monotherapy | 4% (0.2 mg) · 9% (0.4 mg) | Versus 0% placebo; clearly dose-related |
| Constipation — Kapvay paediatric monotherapy | 1% (0.2 mg) · 6% (0.4 mg) | Versus 0% placebo; dose-related |
| Dry mouth — Kapvay paediatric monotherapy | 0% (0.2 mg) · 5% (0.4 mg) | Versus 1% placebo; less prominent than with adult IR tablet |
| Dizziness — Kapvay paediatric monotherapy | 7% (0.2 mg) · 3% (0.4 mg) | Versus 5% placebo |
| Nausea — Kapvay paediatric monotherapy | 4–5% | Versus 3% placebo |
| Bradycardia — Kapvay paediatric monotherapy | 4% (0.4 mg) | Versus 0% placebo; document baseline HR before titration |
| Decreased appetite — Kapvay adjunctive to stimulant | 6% | Versus 3% placebo plus stimulant |
| Tearfulness, aggression, sleep terror, enuresis — Kapvay paediatric | ~1–4% | Each occurred at ≥2% in at least one active dose group |
| Erectile dysfunction / decreased libido — Catapres adult HTN | Listed in PI without precise % | Reported as a reason for dropout in adult clinical trials; usually reversible on discontinuation |
| Dry nasal mucosa — Catapres adult HTN | Less frequent (no PI %) | Listed under oro-otolaryngeal effects in the Catapres PI |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Rebound hypertension on abrupt discontinuation (with reports of hypertensive encephalopathy, CVA, and death) | Class effect; greater at higher doses and with concurrent beta-blocker | Within ~18–36 h of stopping | Reinitiate clonidine (oral); IV phentolamine if severe; taper slowly; daily BP monitoring |
| Symptomatic hypotension / orthostasis | Uncommon overall; up to 45% in epidural Duraclon trial | Days to weeks; greater at dose increases; first 4 days for epidural | Reduce or hold dose; review concomitant antihypertensives; close monitoring during epidural initiation |
| Symptomatic bradycardia / sinus node dysfunction / AV block | Rare; postmarketing reports include need for IV atropine, isoproterenol, and temporary pacing | Variable; greater risk with concurrent sympatholytic drugs | ECG; cardiology evaluation; usually requires discontinuation |
| Syncope | Uncommon | During titration or with dehydration/heat | Withhold dose; reduce or change agent; counsel on hydration |
| Hypersensitivity reactions (generalized rash, urticaria, angioedema) | Rare | Any time; cross-reactivity may occur between transdermal and oral forms | Discontinue; supportive care; future use contraindicated |
| Hallucinations, delirium, or vivid dreams | Listed in Catapres PI; postmarketing for Kapvay; very rare | Variable | Discontinue; psychiatric evaluation |
| QT prolongation | Listed as Kapvay postmarketing report; very rare | Variable; risk amplified by other QT-prolonging drugs | Review concomitant medications; ECG if cardiac risk factors |
| CNS depression in overdose (bradycardia, hypotension, respiratory depression, miosis — opioid-mimicking picture) | Pediatric ingestions of as little as 0.1 mg have produced toxicity | Within 30 min–2 h of ingestion | Supportive care; activated charcoal if recent; IV fluids and atropine for bradycardia; naloxone may help respiratory depression but can paradoxically worsen hypertension |
| Reason for Discontinuation | Approx. Incidence (Paediatric Kapvay Monotherapy) | Context |
|---|---|---|
| Somnolence / sedation | ~5% | Most common cause overall; rises substantially at the 0.4 mg/day dose |
| Fatigue / lethargy | ~4% | Often persistent and dose-related |
| Skin reactions (Catapres-TTS patch) | Common with long-term use | Most common cause of stopping the transdermal formulation specifically |
| Sexual dysfunction (adult HTN) | Listed in PI as dropout reason | Among the reasons cited for discontinuation in historical Catapres tablet trials |
Sedation is dose-related and the leading cause of discontinuation, especially at 0.4 mg/day. Strategies that improve tolerability without abandoning therapy: (1) advance dose by 0.1 mg only every 1–2 weeks rather than weekly in sensitive patients; (2) load the larger split dose at bedtime as the Kapvay label embeds (or use Onyda XR’s once-nightly schedule); (3) reassess concurrent CNS depressants (antihistamines, anticonvulsants, sleep aids); (4) consider switching to guanfacine, which is more α2A-selective and typically less sedating, when sedation persists.
Drug Interactions
The clonidine prescribing information lists few pharmacokinetic interactions; the major clinically significant interactions are pharmacodynamic, with additive effects on blood pressure, heart rate, AV-nodal conduction, and central depression. The combination of beta-blocker therapy with clonidine withdrawal is a particular hazard.
Monitoring
The Kapvay, Onyda XR, and Catapres prescribing information specify measuring blood pressure and heart rate prior to initiation, after dose increases, and periodically while on therapy. Withdrawal monitoring is the highest-yield surveillance for clonidine and applies to every formulation.
-
Blood pressure
Baseline; after each dose change; periodically thereafter
Routine Document seated and standing values during titration. Symptomatic orthostasis or excessive lowering warrants pause and reassessment. -
Heart rate
Baseline; after each dose change; periodically thereafter
Routine Symptomatic bradycardia or HR below age-appropriate norms warrants dose review. -
ECG
If cardiac history or concomitant AV-blocking drugs
Trigger-based Indicated when there is a personal or family history of structural heart disease, sudden death, arrhythmia, or use of beta-blockers, digoxin, diltiazem, or verapamil. -
Renal function
Baseline; periodically if CKD or elderly
Routine 40–60% renal excretion of unchanged drug; half-life rises substantially in advanced impairment, requiring dose reduction. -
Sedation & alertness
Each visit during titration
Routine Sedation is the most common dose-limiting effect; persistent functional impairment warrants dose reduction or switch. -
ADHD response
Baseline; reassess at 4–6 weeks
Routine Use validated rating scales (Vanderbilt, SNAP-IV, ADHD-RS) at home and school for sensitivity to change. -
Patch site (Catapres-TTS)
At each weekly change
Routine Inspect for erythema, vesiculation, or contact dermatitis; rotate site weekly. Cross-reactivity with oral clonidine has been reported in patch-sensitised patients. -
Withdrawal symptoms
During any planned or unplanned dose reduction
Routine Headache, agitation, tachycardia, and rebound BP rise within 1–2 days of stopping; greater risk if on beta-blocker. -
Mood & behaviour
Each visit during early therapy
Routine Ask about mood change, irritability, nightmares, and unusual experiences. Hallucinations are listed in the Catapres PI and as Kapvay postmarketing reports. -
Adherence & access
Each visit; before any planned discontinuation
Routine Patients should never run out. Children with vomiting illness are at particular risk for unintentional rebound hypertension.
Contraindications & Cautions
Absolute Contraindications — All Formulations
- History of hypersensitivity to clonidine or product excipients. Reactions have included generalized rash, urticaria, and angioedema. Patch-sensitised patients may also react to oral formulations.
Absolute Contraindications — Duraclon (Epidural) Specifically
- Anticoagulant therapy — risk of catheter-site haematoma.
- Bleeding diathesis.
- Injection-site infection.
- Administration above the C4 dermatome — no adequate safety data.
Relative Contraindications — Specialist Input Recommended
- Pre-existing heart block, sinus node dysfunction, or significant baseline bradycardia — cardiology input before initiation.
- History of syncope or conditions predisposing to syncope (orthostatic hypotension, dehydration).
- Recent myocardial infarction or unstable cardiovascular disease.
- Cerebrovascular disease — risk of cerebral hypoperfusion with abrupt BP lowering and of stroke with rebound hypertension.
- Severe renal impairment — reduce dose; specialist input recommended.
- Concurrent beta-blocker therapy — greatly increases the danger of rebound hypertension if either drug is stopped abruptly.
- Duraclon for obstetric, postpartum, or perioperative pain — per the FDA label, not recommended due to risk of hemodynamic instability; benefit may rarely outweigh risk in selected patients.
Use with Caution
- Pheochromocytoma — per Catapres PI, no therapeutic effect can be expected in pheochromocytoma-related hypertension.
- Elderly patients — higher orthostatic hypotension and fall risk.
- Patients on multiple antihypertensives or sedating drugs — additive effects likely.
- Pregnancy — long human experience without identified teratogenicity; use if benefit outweighs risk and consider the National Pregnancy Registry for ADHD Medications (1-866-961-2388) when used for ADHD.
- Lactation — clonidine is excreted in milk (relative infant dose 4–8% of maternal weight-adjusted dose); observe nursing infants for sedation, hypotonia, and apnea.
- Operating heavy machinery or driving — particularly during titration.
- Children with intercurrent vomiting illness — missed doses can lead to rebound hypertension.
- Households with young children — per the Catapres PI, as little as 0.1 mg has produced toxicity in children. Counsel on secure storage of all formulations.
The Catapres prescribing information warns that abrupt cessation of clonidine has resulted in nervousness, agitation, headache, and tremor accompanied or followed by a rapid rise in blood pressure and elevated plasma catecholamines. Rare instances of hypertensive encephalopathy, cerebrovascular accident, and death have been reported after clonidine withdrawal — particularly when the patient has continued a beta-blocker. The risk is greatest at higher doses and after prolonged use. The Kapvay and Onyda XR labels carry the same warning, extrapolated from the immediate-release withdrawal data, although controlled withdrawal studies in paediatric ADHD have not been conducted.
To minimize this risk, taper clonidine in decrements of no more than 0.1 mg every 3–7 days (Kapvay and Onyda XR labels) or gradually over 2–4 days (Catapres tablet label). When co-administered with a beta-blocker, withdraw the beta-blocker several days before discontinuing clonidine. An excessive rise in BP following discontinuation can be reversed with reinstitution of oral clonidine or with intravenous phentolamine.
Patient Counselling
Purpose of Therapy
Clonidine has several uses. For high blood pressure, it acts in the brain to reduce the nerve signals that constrict blood vessels and speed up the heart. For ADHD, the extended-release tablet (Kapvay) and oral suspension (Onyda XR) are non-stimulant alternatives or add-ons; benefit usually develops over 2–4 weeks rather than within hours like stimulants. For withdrawal from opioids or alcohol, clonidine eases the autonomic symptoms (sweating, agitation, fast heart rate) but does not prevent seizures. For hot flashes, the effect is modest. For severe cancer pain, an epidural infusion of clonidine (Duraclon) can supplement opioid analgesia.
How to Take
The regular tablet (Catapres) is taken twice daily, with the larger dose at bedtime to reduce daytime drowsiness. The extended-release tablet (Kapvay) must be swallowed whole, never crushed or chewed; it is taken twice daily with an equal or larger dose at bedtime. The oral suspension (Onyda XR) is taken once nightly at bedtime; gently shake the bottle and use the supplied dispenser. The patch (Catapres-TTS) is changed once weekly and applied to a clean, hairless area of the upper outer arm or chest; rotate sites with each change. Wash hands after handling the patch. Never stop clonidine suddenly — missing doses or running out can cause a dangerous spike in blood pressure.
Sources
- Kapvay (clonidine hydrochloride) extended-release tablets — full prescribing information. U.S. Food and Drug Administration. Available at accessdata.fda.gov Primary source for paediatric ADHD dosing tables, fixed-dose adverse-event tables, and discontinuation rates.
- Catapres (clonidine hydrochloride) tablets — full prescribing information. U.S. Food and Drug Administration. Available at accessdata.fda.gov Primary source for adult hypertension dosing, oral pharmacokinetics, the rebound hypertension warning, and side-effect rates (dry mouth 40%, drowsiness 33%, dizziness 16%, constipation 10%, sedation 10%).
- Catapres-TTS (clonidine transdermal system) — full prescribing information. U.S. Food and Drug Administration. Available at accessdata.fda.gov Primary source for patch sizing (TTS-1, -2, -3 delivering 0.1, 0.2, 0.3 mg/day), application, and transdermal pharmacokinetics.
- Onyda XR (clonidine hydrochloride) extended-release oral suspension — full prescribing information. U.S. Food and Drug Administration; approved May 2024. Available at accessdata.fda.gov Primary source for once-nightly oral suspension dosing (max 0.4 mg HS) and titration schedule.
- Duraclon (clonidine hydrochloride) injection — full prescribing information. U.S. Food and Drug Administration. Available at accessdata.fda.gov Primary source for epidural cancer-pain dosing (30 mcg/h starting), formal contraindications (anticoagulation, bleeding diathesis, injection-site infection, above C4 dermatome), and the 45% pivotal trial hypotension rate.
- Jain R, Segal S, Kollins SH, Khayrallah M. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50(2):171–179. doi:10.1016/j.jaac.2010.11.005 Pivotal Kapvay monotherapy trial in paediatric ADHD (Study CLON-301).
- Kollins SH, Jain R, Brams M, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics. 2011;127(6):e1406–e1413. doi:10.1542/peds.2010-1260 Pivotal Kapvay adjunctive-to-stimulant trial supporting combination-therapy approval.
- Gowing L, Farrell M, Ali R, White JM. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev. 2016;(5):CD002024. doi:10.1002/14651858.CD002024.pub5 Cochrane systematic review supporting clonidine and lofexidine for opioid withdrawal symptom management.
- Eisenach JC, DuPen S, Dub M, et al. Epidural clonidine analgesia for intractable cancer pain. Pain. 1995;61(3):391–399. doi:10.1016/0304-3959(94)00209-W Pivotal trial of epidural clonidine for severe cancer pain that supported the Duraclon FDA approval.
- Wolraich ML, Hagan JF, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. American Academy of Pediatrics. Pediatrics. 2019;144(4):e20192528. doi:10.1542/peds.2019-2528 Current AAP guideline addressing the place of clonidine and guanfacine among non-stimulant ADHD options.
- Pringsheim T, Okun MS, Mller-Vahl K, et al. Practice guideline recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. American Academy of Neurology. Neurology. 2019;92(19):896–906. doi:10.1212/WNL.0000000000007466 AAN guideline supporting α2-agonists, including clonidine, as treatment options for tic disorders.
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension. 2018;71(6):e13–e115. doi:10.1161/HYP.0000000000000065 U.S. hypertension guideline; positions clonidine as a non-first-line antihypertensive reserved for resistant or specific clinical scenarios.
- The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573–590. doi:10.1097/GME.0000000000002200 NAMS guideline addressing clonidine’s role and limitations in non-hormonal management of menopausal vasomotor symptoms.
- Giovannitti JA Jr, Thoms SM, Crawford JJ. Alpha-2 adrenergic receptor agonists: a review of current clinical applications. Anesth Prog. 2015;62(1):31–39. doi:10.2344/0003-3006-62.1.31 Review of clonidine and dexmedetomidine pharmacology, α2-receptor subtypes, and clinical applications including perioperative use.
- Yasaei R, Saadabadi A. Clonidine. In: StatPearls. Treasure Island (FL): StatPearls Publishing; updated 2024. Available at ncbi.nlm.nih.gov/books/NBK459124 Comprehensive overview of clonidine pharmacology, indications, and toxicology; documents Vd of 2.1 ± 0.4 L/kg and CYP2D6’s predominant role in non-renal clearance.
- Lowenthal DT, Matzek KM, MacGregor TR. Clinical pharmacokinetics of clonidine. Clin Pharmacokinet. 1988;14(5):287–310. doi:10.2165/00003088-198814050-00002 Foundational pharmacokinetic review including renal-impairment data (half-life prolongation up to ~41 h).
- Amna S, Naqvi SBS, Tanwir S, Rasheed K. Review of clinical pharmacokinetics and pharmacodynamics of clonidine as an adjunct to opioids in palliative care. Basic Clin Pharmacol Toxicol. 2024;134(4):485–497. doi:10.1111/bcpt.13979 Recent comprehensive PK/PD review confirming volume of distribution (~2.1 L/kg) and characterizing clonidine’s role in palliative analgesia.